|
CHANGE IN BODY WEIGHT AFTER THE TRANSITION TO
DOLUTEGRAVIR-BASED ANTIRETROVIRAL THERAPY, (COMPLICATIONS WORKSHOP)
|
|
|
Dec 7 2022
The author presenter in explaining why the weight increases were so much less than seen in ADVANCE - in this study TDF was used not TAF in ADVANCE; these were patients already with viral suppression not naives like in ADVANCE; ADVANCE was in South Africa where obesity , in the South Africa Demographic and Health Survey in 2016 (before the switch to DTG) found that 2 in 3 women and 1 in 3 men were already overweight or obese prior to the national program's transition. This may exacerbate the magnitude of weight gain in the population related to ART, this study was in Uganda, its suspected obesity epidemic may be less accelerated in this geography than in a place like South Africa, where obesity is rising very rapidly. That hypothesis was in part based on some background research in another cohort from this area where rates of Physical Activity as a part of daily activities were still very high.
how much the magnitude and extent of weight gain in various settings relates to the background obesity epidemic
|
|
|
|
|
|
|